MNG649
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.301
- MITOTIC_SPINDLE+0.177
- E2F_TARGETS+0.158
- ESTROGEN_RESPONSE_EARLY+0.152
- FATTY_ACID_METABOLISM+0.149
- G2M_CHECKPOINT+0.140
- PEROXISOME+0.127
- PROTEIN_SECRETION+0.115
- APICAL_SURFACE+0.110
- PI3K_AKT_MTOR_SIGNALING+0.094
Top 10 suppressed
- MYC_TARGETS_V2-0.422
- TNFA_SIGNALING_VIA_NFKB-0.420
- MYC_TARGETS_V1-0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.315
- INFLAMMATORY_RESPONSE-0.302
- INTERFERON_GAMMA_RESPONSE-0.294
- APOPTOSIS-0.286
- WNT_BETA_CATENIN_SIGNALING-0.283
- UV_RESPONSE_DN-0.277
- PANCREAS_BETA_CELLS-0.269
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-ZF-AA4X-01A-11R-A38B-07 | — | — | 0.807 |
| 2 | MDT-AP-2068 | Med | Medulloblastoma | 0.801 |
| 3 | MNG13 | — | — | 0.759 |
| 4 | DRR168586 | — | — | 0.753 |
| 5 | MNG400 | — | — | 0.752 |
| 6 | TCGA-LL-A442-01A-11R-A24H-07 | — | B | 0.748 |
| 7 | MDT-AP-0840 | Med | Medulloblastoma | 0.744 |
| 8 | TCGA-CR-6480-01A-11R-1873-07 | — | — | 0.740 |
| 9 | TCGA-HD-8314-01A-11R-2403-07 | — | — | 0.728 |
| 10 | TCGA-GU-A42P-01A-11R-A23W-07 | — | — | 0.727 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.301 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.177 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.158 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.152 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.149 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.140 | Inavolisib | — uncovered |
| PEROXISOME | 0.127 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.115 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.094 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.083 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.074 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.062 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.053 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.052 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.049 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.042 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.040 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.019 | Inavolisib | — uncovered |